Quantcast

Latest Epidermolysis bullosa Stories

2014-06-12 08:28:59

DURHAM, N.C., June 12, 2014 /PRNewswire/ -- Scioderm, Inc. today announced the addition of Ronald Nardi, Ph.D. as the company's first chief scientific officer. Key points: -- Dr. Nardi brings more than 35 years of experience in drug discovery, development and regulatory affairs and was most recently the executive vice president of regulatory affairs and quality assurance at International Partnership for Microbicides. -- Dr. Nardi was previously the chief...

2014-04-01 08:28:31

DURHAM, N.C., April 1, 2014 /PRNewswire/ -- Scioderm, Inc. today announced it has completed enrollment of its Phase 2b study (SD-003) to evaluate the safety and efficacy of SD-101, a novel topical therapy for the treatment of blisters and lesions in patients with Epidermolysis Bullosa (EB.) Key points: -- Epidermolysis Bullosa (EB) is a rare, genetic connective tissue disorder that typically manifests at birth or early childhood. -- All forms of EB share the common symptom...

2014-01-22 08:28:52

DURHAM, N.C., Jan. 22, 2014 /PRNewswire/ -- Scioderm, Inc., today announced that the European Commission (EC) has granted orphan drug designation for SD-101 for the treatment of patients with Epidermolysis Bullosa (EB), a group of rare genetic skin diseases. This decision follows a positive opinion adopted by the Committee for Orphan Medicinal Products (COMP), recommending such designation. Epidermolysis Bullosa is a rare genetic connective tissue condition that, in all of its...

2014-01-07 08:30:32

DURHAM, N.C., Jan. 7, 2014 /PRNewswire/ -- Scioderm, Inc., today announced that Dr. Robert Ryan, President and Chief Executive Officer of Scioderm, was invited to present at the 32nd Annual J.P. Morgan Healthcare Conference at 7:30 a.m. Pacific Standard Time (10:30 a.m. EST) on Thursday, January 16, 2014 in the Elizabethan C/D room of the Westin St. Francis hotel. Dr. Ryan will discuss the company's lead investigational therapy, SD-101, currently in late stage clinical development...

2014-01-06 08:26:03

DURHAM, N.C., Jan. 6, 2014 /PRNewswire/ -- Scioderm, Inc. today announced the initiation of a Phase 2B study designed to evaluate the efficacy and safety of SD-101, a novel topical therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a rare, genetic connective tissue disorder that typically manifests at birth or early childhood. "People affected by EB suffer skin blisters, chronic wounds, almost constant pain and itching, and scarring," said...

2013-12-27 10:29:35

Stem cell-based gene therapy holds promise for the treatment of devastating genetic skin diseases, but the long-term clinical outcomes of this approach have been unclear. In a study online December 26th in the ISSCR's journal Stem Cell Reports, published by Cell Press, researchers evaluated a patient with a genetic skin disorder known as epidermolysis bullosa (EB) nearly seven years after he had undergone a gene therapy procedure as part of a clinical trial. The study revealed that a small...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related